Aptamers: Therapeutics, Technologies, and Services Market | #aptamer # aptamers-based therapeutics # aptamer-based therapies # aptamer technologies # Market Insights # Market Research

新聞與政治

Aptamers: Therapeutics, Technologies, and Services Market

Aptamers have gained a lot of momentum in the past decade. It is worth highlighting that in 2005, Macugen became the first and the only USFDA approved aptamer drug for treating age-related macular degeneration (AMD).

The companion diagnostics development services market, is anticipated to grow at a CAGR of over 10% | #companion Diagnostics # companion diagnostics development # companion diagnostics market size # personalized medicine # Market Insights # Market Research

新聞與政治

The companion diagnostics development services market, is anticipated to grow at a CAGR of over 10%

Given the various challenges associated with co-development of companion diagnostics and drug / therapy, drug developers prefer to rely on third-party service providers that offer customized services and advanced technologies.

The cell invasion and migration assays market is projected to grow at a CAGR of 8% | #cell Invasion and Migration Assays Market # cell invasion # cell-based assays # cell migration assays # Market Insights # Market Research

新聞與政治

The cell invasion and migration assays market is projected to grow at a CAGR of 8%

In recent years, the potential of cell invasion and migration assays with respect to discovery, diagnosis and screening of diseases has been widely recognized, which has further presented lucrative opportunities for players offering such products.

The novel antibody therapies market for advanced stage drugs is anticipated to grow at a CAGR of 36% by 2035 | #novel Antibody Therapies Market # antibody therapies # immunotoxins # novel antibody therapies # Market Insights # Market Research

新聞與政治

The novel antibody therapies market for advanced stage drugs is anticipated to grow at a CAGR of 36% by 2035

Owing to the recent approval of therapies, such as Elzonris®, Pluvicto®, there has been a substantial increase in the R&D activity to evaluate the use of novel antibody therapy candidates for the treatment of a variety of disease indications.

The ADC contract manufacturing market is projected to grow at a CAGR of more than 13% till 2035 | #antibody Drug Conjugate # contract manufacturing organizations # ADC # ADC contract manufacturing # Market Research # Market Insights

新聞與政治

The ADC contract manufacturing market is projected to grow at a CAGR of more than 13% till 2035

Owing to the fact that a number of ADC developers are outsourcing various aspects of their business processes, CMOs engaged in this domain have undertaken several expansion initiatives to become one-stop-shops to cater to the diverse needs of ADC developers.